We validated XAB2 as a novel TMZ sensitizer using clonogenic assays with NCH644 cells (GBM cancer stem-like cell line) (Supplementary Figure S1A–C) and U87 cells (GBM adherent cell line) (Supplementary Figure S1D–F) expressing a control, non-silencing shRNA (shCTRL) or two independent shRNAs targeting XAB2. Here, XAB2 is linked to cancer.